# Object Record 0
**objectId:** dashboard-item-1759853783245-patient-context
**type:** component
**componentType:** PatientContext
**description:** 
**content title:** Patient Context
**content component:** PatientContext
**content props patientData patient name:** Sarah Miller
**content props patientData patient date of birth:** 1981-06-03
**content props patientData patient age:** 43
**content props patientData patient sex:** Female
**content props patientData patient age at first encounter:** 43
**content props patientData patient identifiers mrn:** SM43850603
**content props patientData riskLevel:** high
**content props patientData primaryDiagnosis:** Severe Drug-Induced Liver Injury (Methotrexate-related)
**content props patientData problem list 0 name:** Type 2 Diabetes Mellitus
**content props patientData problem list 0 status:** active
**content props patientData problem list 1 name:** Essential Hypertension
**content props patientData problem list 1 status:** active
**content props patientData problem list 2 name:** Rheumatoid Arthritis
**content props patientData problem list 2 status:** active
**content props patientData problem list 3 name:** Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD/MASH)
**content props patientData problem list 3 status:** active
**content props patientData problem list 4 name:** Severe Methotrexate-induced Drug-Induced Liver Injury (DILI)
**content props patientData problem list 4 status:** active
**content props patientData problem list 5 name:** Acute jaundice episode (2024-08)
**content props patientData problem list 5 status:** resolved/improving
**content props patientData medication timeline 0 name:** Metformin
**content props patientData medication timeline 0 dose:** 1000 mg
**content props patientData medication timeline 0 route:** PO
**content props patientData medication timeline 0 frequency:** BD
**content props patientData medication timeline 0 start:** 2019-01-01
**content props patientData medication timeline 1 name:** Ramipril
**content props patientData medication timeline 1 dose:** 5 mg
**content props patientData medication timeline 1 route:** PO
**content props patientData medication timeline 1 frequency:** daily
**content props patientData medication timeline 1 start:** 2020-01-01
**content props patientData medication timeline 2 name:** Ibuprofen
**content props patientData medication timeline 2 dose:** variable
**content props patientData medication timeline 2 route:** PO
**content props patientData medication timeline 2 frequency:** PRN
**content props patientData medication timeline 2 start:** 2022-01-01
**content props patientData medication timeline 3 name:** Simethicone
**content props patientData medication timeline 3 dose:** standard
**content props patientData medication timeline 3 route:** PO
**content props patientData medication timeline 3 frequency:** PRN
**content props patientData medication timeline 3 start:** 2024-03-05
**content props patientData medication timeline 4 name:** Methotrexate
**content props patientData medication timeline 4 dose:** 7.5 mg
**content props patientData medication timeline 4 route:** PO
**content props patientData medication timeline 4 frequency:** weekly
**content props patientData medication timeline 4 start:** 2024-06-03
**content props patientData medication timeline 4 end:** 2024-08-12
**content props patientData medication timeline 5 name:** Folic Acid
**content props patientData medication timeline 5 dose:** 5 mg
**content props patientData medication timeline 5 route:** PO
**content props patientData medication timeline 5 frequency:** weekly
**content props patientData medication timeline 5 start:** 2024-06-03
**content props patientData medication timeline 6 name:** Methotrexate (dose reduced)
**content props patientData medication timeline 6 dose:** 5 mg
**content props patientData medication timeline 6 route:** PO
**content props patientData medication timeline 6 frequency:** weekly
**content props patientData medication timeline 6 start:** 2024-07-15
**content props patientData medication timeline 6 end:** 2024-08-12
**content props patientData medication timeline 7 name:** N-Acetylcysteine (NAC IV)
**content props patientData medication timeline 7 dose:** 3-bag protocol
**content props patientData medication timeline 7 route:** IV
**content props patientData medication timeline 7 frequency:** one-time protocol
**content props patientData medication timeline 7 start:** 2024-08-12
**content props patientData medication timeline 7 end:** 2024-08-17
**content props patientData medication timeline 8 name:** Ursodeoxycholic Acid (UDCA)
**content props patientData medication timeline 8 dose:** 500 mg
**content props patientData medication timeline 8 route:** PO
**content props patientData medication timeline 8 frequency:** BID
**content props patientData medication timeline 8 start:** 2024-08-15
**content props patientData allergies 0:** Methotrexate (severe DILI – permanent contraindication)
**createdAt:** 2025-10-14T16:16:23.245Z
**updatedAt:** 2025-10-14T16:16:23.245Z

# Object Record 1
**objectId:** dashboard-item-1759906076097-medication-timeline
**type:** component
**componentType:** MedicationTimeline
**description:** 
**content title:** Medication Timeline
**content component:** MedicationTimeline
**content props encounters 0 encounter no:** 1
**content props encounters 0 date:** 2024-03-05
**content props encounters 0 type:** General Practice
**content props encounters 0 provider:** Dr. P. Stevens
**content props encounters 0 diagnosis:** Fatigue; Suboptimally controlled T2DM/HTN; RA stable
**content props encounters 0 medications 0:** Metformin 1000mg BD
**content props encounters 0 medications 1:** Ramipril 5mg daily
**content props encounters 0 medications 2:** Ibuprofen PRN
**content props encounters 0 medications 3:** Simethicone PRN
**content props encounters 0 notes:** Initial evaluation; abnormal ALT 78 U/L; lifestyle counselling; HbA1c 58 mmol/mol.
**content props encounters 1 encounter no:** 2
**content props encounters 1 date:** 2024-04-01
**content props encounters 1 type:** General Practice
**content props encounters 1 provider:** Dr. P. Stevens
**content props encounters 1 diagnosis:** Review of elevated ALT; suspected MASLD; RA requiring MTX evaluation
**content props encounters 1 medications 0:** Metformin 1000mg BD
**content props encounters 1 medications 1:** Ramipril 5mg daily
**content props encounters 1 medications 2:** Ibuprofen PRN
**content props encounters 1 medications 3:** Simethicone PRN
**content props encounters 1 notes:** Deferred Methotrexate; ordered hepatitis/autoimmune/metabolic workup.
**content props encounters 2 encounter no:** 3
**content props encounters 2 date:** 2024-05-06
**content props encounters 2 type:** General Practice
**content props encounters 2 provider:** Dr. P. Stevens
**content props encounters 2 diagnosis:** LFT normalization; RA requiring DMARD; MASLD flare resolved
**content props encounters 2 medications 0:** Methotrexate 7.5mg weekly (planned start 2024-06-03)
**content props encounters 2 medications 1:** Folic Acid 5mg weekly
**content props encounters 2 medications 2:** Metformin 1000mg BD
**content props encounters 2 medications 3:** Ramipril 5mg daily
**content props encounters 2 medications 4:** Ibuprofen PRN
**content props encounters 2 medications 5:** Simethicone PRN
**content props encounters 2 notes:** Cleared for MTX; full hepatitis, autoimmune, metabolic workup negative.
**content props encounters 3 encounter no:** 4
**content props encounters 3 date:** 2024-06-03
**content props encounters 3 type:** General Practice
**content props encounters 3 provider:** Dr. P. Stevens
**content props encounters 3 diagnosis:** Initiation of Methotrexate therapy for RA
**content props encounters 3 medications 0:** Methotrexate 7.5mg weekly (started today)
**content props encounters 3 medications 1:** Folic Acid 5mg weekly
**content props encounters 3 medications 2:** Metformin 1000mg BD
**content props encounters 3 medications 3:** Ramipril 5mg daily
**content props encounters 3 notes:** MTX started; monitoring schedule established (LFT/FBC q6 weeks).
**content props encounters 4 encounter no:** 5
**content props encounters 4 date:** 2024-07-15
**content props encounters 4 type:** General Practice
**content props encounters 4 provider:** Dr. P. Stevens
**content props encounters 4 diagnosis:** Severe hepatocellular DILI from Methotrexate; RA symptoms improving
**content props encounters 4 medications 0:** Methotrexate reduced to 5mg weekly
**content props encounters 4 medications 1:** Folic Acid 5mg weekly
**content props encounters 4 medications 2:** Metformin 1000mg BD
**content props encounters 4 medications 3:** Ramipril 5mg daily
**content props encounters 4 notes:** ALT 185 U/L (~4.6× ULN); MTX dose reduced (though standard is to stop); hepatology referral placed.
**content props encounters 5 encounter no:** 6
**content props encounters 5 date:** 2024-08-12
**content props encounters 5 type:** Emergency Department
**content props encounters 5 provider:** ED team + handover from Dr. Stevens
**content props encounters 5 diagnosis:** Severe acute DILI with cholestasis; jaundice; bilirubin 110 μmol/L
**content props encounters 5 medications 0:** Methotrexate stopped
**content props encounters 5 medications 1:** N-Acetylcysteine (NAC) IV protocol initiated
**content props encounters 5 notes:** Urgent hospitalization; ALT 490 U/L (12× ULN); NAC started; admitted to hepatology ward.
**content props encounters 6 encounter no:** 7
**content props encounters 6 date:** 2024-08-15
**content props encounters 6 type:** Inpatient Hepatology
**content props encounters 6 provider:** Dr. R. Sharma (Consultant Hepatologist)
**content props encounters 6 diagnosis:** Severe MTX-induced DILI with MASH; improving ALT; worsening jaundice
**content props encounters 6 medications 0:** NAC protocol (continuing until 2024-08-17)
**content props encounters 6 medications 1:** Ursodeoxycholic Acid (UDCA) 500mg BID
**content props encounters 6 medications 2:** Folic Acid (continued)
**content props encounters 6 notes:** Methotrexate added to permanent contraindication list; ALT decreasing to 420; bilirubin rising to 190.
**content props medicationTimeline 0 name:** Metformin
**content props medicationTimeline 0 startDate:** 2019-01-01
**content props medicationTimeline 0 dose:** 1000mg BD
**content props medicationTimeline 0 indication:** Type 2 Diabetes Mellitus
**content props medicationTimeline 1 name:** Ramipril
**content props medicationTimeline 1 startDate:** 2020-01-01
**content props medicationTimeline 1 dose:** 5mg daily
**content props medicationTimeline 1 indication:** Hypertension
**content props medicationTimeline 2 name:** Ibuprofen
**content props medicationTimeline 2 startDate:** 2022-01-01
**content props medicationTimeline 2 dose:** PRN
**content props medicationTimeline 2 indication:** Rheumatoid arthritis pain
**content props medicationTimeline 3 name:** Simethicone
**content props medicationTimeline 3 startDate:** 2024-03-05
**content props medicationTimeline 3 dose:** PRN
**content props medicationTimeline 3 indication:** Bloating/gas symptoms
**content props medicationTimeline 4 name:** Methotrexate
**content props medicationTimeline 4 startDate:** 2024-06-03
**content props medicationTimeline 4 endDate:** 2024-07-15
**content props medicationTimeline 4 dose:** 7.5mg weekly
**content props medicationTimeline 4 indication:** Rheumatoid Arthritis
**content props medicationTimeline 5 name:** Methotrexate
**content props medicationTimeline 5 startDate:** 2024-07-15
**content props medicationTimeline 5 endDate:** 2024-08-12
**content props medicationTimeline 5 dose:** 5mg weekly
**content props medicationTimeline 5 indication:** Rheumatoid Arthritis (dose reduction due to hepatotoxicity)
**content props medicationTimeline 6 name:** Folic Acid
**content props medicationTimeline 6 startDate:** 2024-06-03
**content props medicationTimeline 6 dose:** 5mg weekly
**content props medicationTimeline 6 indication:** MTX toxicity prophylaxis
**content props medicationTimeline 7 name:** N-Acetylcysteine (IV)
**content props medicationTimeline 7 startDate:** 2024-08-12
**content props medicationTimeline 7 endDate:** 2024-08-17
**content props medicationTimeline 7 dose:** 3-bag IV protocol
**content props medicationTimeline 7 indication:** Acute severe DILI
**content props medicationTimeline 8 name:** Ursodeoxycholic Acid (UDCA)
**content props medicationTimeline 8 startDate:** 2024-08-15
**content props medicationTimeline 8 dose:** 500mg BID
**content props medicationTimeline 8 indication:** Cholestasis/jaundice
**createdAt:** 2025-10-14T16:47:56.098Z
**updatedAt:** 2025-11-18T09:15:31.732Z

# Object Record 24
**objectId:** dashboard-item-hepato-referal-decline
**type:** button
**buttonText:** Decline Hepatologist Referral
**buttonIcon:** 
**buttonColor:** #F44336
**buttonAction:** declineHepato
**showHandles:** True
**handlePosition:** left
**draggable:** False
**createdAt:** 2025-11-10T16:00:00.000Z
**updatedAt:** 2025-11-10T16:00:00.000Z

# Object Record 3
**objectId:** dashboard-item-1759906300004-single-encounter-4
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #4 - Outpatient
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 4
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2024-06-03T11:30:55
**content props encounter meta provider name:** Dr. P. Stevens
**content props encounter meta provider specialty:** Unknown
**content props encounter meta ui risk color:** yellow
**content props encounter assessment impression:** Initiation of Methotrexate for Rheumatoid Arthritis management.
**content props encounter chief complaint:** Initiation of Disease-Modifying Anti-Rheumatic Drug (DMARD) - Methotrexate (MTX) for Rheumatoid Arthritis (RA) management.
**content props encounter hpi:** Sarah Miller presents for the initiation of Methotrexate treatment for RA. She reports her joint pain has been stable but remains a significant source of discomfort, affecting her daily activities. A thorough review of her medical history, medication adherence, and lifestyle was conducted. The patient confirms receipt and comprehension of the Methotrexate informational leaflet, indicating understanding of the treatment regimen and potential adverse effects. The decision to commence Methotrexate was made following normalization of liver function tests (LFTs) as of May 6, 2024. The patient reiterated understanding of the importance of strict compliance with the monitoring schedule due to the severe hepatotoxicity risk associated with Methotrexate.
**content props encounter physical exam general:** Vital Signs: BP 138/86 mmHg (sitting), HR 80 bpm, RR 15/min, Temp 36.7°C, SpO₂ 98% on room air. Anthropometrics: Weight 84 kg (BMI 31.2 kg/m²). Weight stable compared with early May.
**content props encounter physical exam msk:** 
**content props encounter physical exam other systems:** 
**content props encounter plan investigations labs 0:** LFTs every six weeks
**content props encounter plan investigations labs 1:** Full Blood Count (FBC) every six weeks
**content props encounter plan management follow up:** First LFT/FBC evaluation scheduled for July 15, 2024. Regular monitoring every six weeks for the next 6 months. Patient to contact clinic immediately if severe nausea, vomiting, or jaundice occur.
**content props encounter plan management medications started 0 dose:** 7.5mg
**content props encounter plan management medications started 0 frequency:** once weekly
**content props encounter plan management medications started 0 name:** Methotrexate
**content props encounter plan management medications started 0 route:** orally
**content props encounter plan management medications started 1 dose:** 5mg
**content props encounter plan management medications started 1 frequency:** weekly
**content props encounter plan management medications started 1 name:** Folic Acid
**content props encounter plan management medications started 1 route:** orally
**content props encounter reason for visit:** Initiation of Methotrexate for Rheumatoid Arthritis management.
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 43
**content props encounterIndex:** 4
**content props dataSource:** Medilogik
**createdAt:** 2025-10-15T08:00:00.000Z
**updatedAt:** 2025-10-15T08:00:00.000Z

# Object Record 0
**objectId:** dashboard-item-1759906300003-single-encounter-1
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #1 - Outpatient Visit
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 1
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2024-03-05T10:15:22Z
**content props encounter meta provider name:** Dr. P. Stevens
**content props encounter meta provider specialty:** General Practice
**content props encounter meta ui risk color:** yellow
**content props encounter assessment impression:** Suboptimal control of T2DM/HTN, Chronic Fatigue Syndrome possibly related to MASLD. Diabetes control is poor with HbA1c at 58 mmol/mol, indicating long-standing hyperglycaemia and need for therapeutic adjustment.
**content props encounter assessment differential 0:** T2DM suboptimal control
**content props encounter assessment differential 1:** Hypertension suboptimal control
**content props encounter assessment differential 2:** Chronic Fatigue Syndrome
**content props encounter assessment differential 3:** MASLD
**content props encounter chief complaint:** Increased fatigue over the past 4-5 months
**content props encounter hpi:** Sarah Miller, a 43-year-old administrative assistant, presents with debilitating fatigue affecting work performance. She averages 6.5 hours of non-restorative sleep per night and experiences RA-related discomfort, particularly in the right wrist. She takes Ibuprofen 4-5 times per week for pain and chemically-induced frequent bloating. HbA1c from today’s labs is 58 mmol/mol, confirming persistently weak glycaemic control which may be contributing to fatigue and metabolic strain.
**content props encounter medications prior 0 name:** Metformin
**content props encounter medications prior 0 route:** Oral, unknown dose, BD frequency, for T2DM
**content props encounter medications prior 1 name:** Ramipril
**content props encounter medications prior 1 route:** Oral, 5mg, OD frequency, for Hypertension
**content props encounter medications prior 2 name:** Ibuprofen
**content props encounter medications prior 2 route:** Oral, unknown dose, taken 4-5 times per week for RA pain
**content props encounter medications prior 3 name:** Simethicone
**content props encounter medications prior 3 route:** Oral, unknown dose, unknown frequency, for bloating
**content props encounter physical exam general:** Appears non-toxic and well-perfused.
**content props encounter physical exam msk:** Mild effusion in right MCP joint 3, mild pain on movement.
**content props encounter physical exam other systems:** Vital Signs: BP 146/92 mmHg (sitting), HR 82 bpm, RR 16/min, Temp 36.8°C, SpO₂ 99% on room air. Anthropometrics: Height 1.64 m, Weight 86 kg (BMI 32.0 kg/m²; class I obesity). Weight reported as broadly stable over the past 12 months. Skin/Sclera: Anicteric sclerae; no chronic liver disease stigmata. Abdomen: Soft, lax, normal liver span, no tenderness. Diabetes: Persistent hyperglycaemia suspected based on elevated HbA1c and obesity.
**content props encounter plan investigations labs 0:** Complete LFTs
**content props encounter plan investigations labs 1:** HbA1c
**content props encounter plan investigations labs 2:** Consider future intensification of diabetes therapy if HbA1c remains > 53 mmol/mol
**content props encounter plan management follow up:** Follow-up in 4 weeks to evaluate LFTs and MTX eligibility.
**content props encounter reason for visit:** Increased fatigue
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 43
**content props encounterIndex:** 1
**content props dataSource:** Electronic Health Record
**createdAt:** 2025-10-14T16:55:00.003Z
**updatedAt:** 2025-10-14T16:55:00.003Z

# Object Record 4
**objectId:** dashboard-item-1759906300004-single-encounter-5
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #5 - Outpatient
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 5
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2024-07-15T14:00:30
**content props encounter meta provider name:** Dr. P. Stevens
**content props encounter meta provider specialty:** Rheumatology
**content props encounter meta ui risk color:** yellow
**content props encounter assessment impression:** Methotrexate-induced Drug-Induced Liver Injury (DILI) presenting with elevated ALT (185 U/L, 4.6x ULN), with new intermittent nausea and increased fatigue. Rheumatoid arthritis symptoms are improving on Methotrexate. Diabetes control has deteriorated with HbA1c rising to 60 mmol/mol, signalling worsening glycaemia during MTX therapy and possible contribution to fatigue.
**content props encounter assessment differential 0:** Methotrexate-induced Drug-Induced Liver Injury (DILI)
**content props encounter assessment differential 1:** Underlying MASLD risk factors
**content props encounter chief complaint:** Routine Methotrexate (MTX) monitoring. Reports of new intermittent nausea and increased fatigue.
**content props encounter hpi:** Sarah Miller, a 43-year-old female, presents for routine Methotrexate monitoring. She reports ~1 kg unintentional weight loss over the past month, attributed to reduced appetite and intermittent nausea, primarily in the evenings. No vomiting or diarrhea. Fatigue levels have returned to pre-MTX initiation severity. Rheumatoid arthritis symptoms have significantly improved with diminished joint pain and increased daily function since starting Methotrexate. Recent labs show ALT elevated to 185 U/L (4.6x ULN). HbA1c has worsened to 60 mmol/mol, indicating declining diabetes control despite weight loss.
**content props encounter physical exam general:** Vital Signs: BP 144/92 mmHg (sitting), HR 88 bpm, RR 16/min, Temp 36.8°C, SpO₂ 98% on room air.
**content props encounter physical exam msk:** Joint pain has diminished.
**content props encounter physical exam other systems:** Weight 83 kg (BMI 30.8 kg/m²). Despite some weight reduction, diabetes control is worsening with higher HbA1c and increased metabolic fatigue.
**content props encounter plan investigations labs 0:** Repeat liver function tests in four weeks
**content props encounter plan investigations labs 1:** HbA1c monitoring recommended due to recent deterioration
**content props encounter plan management follow up:** Follow up in four weeks. Advised to remain vigilant for any worsening of symptoms or new signs of liver dysfunction such as jaundice, further exacerbated fatigue, or darker urine. Ensure adherence to adjusted Methotrexate regimen. Attend Hepatology consultation.
**content props encounter plan management medications started 0 dose:** 5mg
**content props encounter plan management medications started 0 frequency:** weekly
**content props encounter plan management medications started 0 name:** Methotrexate
**content props encounter plan management medications started 0 route:** 
**content props encounter reason for visit:** Routine Methotrexate monitoring and management of new symptoms of nausea and fatigue, and elevated liver enzymes.
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 43
**content props encounterIndex:** 5
**content props dataSource:** Nervecentre
**createdAt:** 2025-10-15T08:00:00.000Z
**updatedAt:** 2025-10-15T08:00:00.000Z

# Object Record 2
**objectId:** dashboard-item-1759906300004-single-encounter-3
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #3 - Outpatient Follow-up
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 3
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2024-05-06T09:00:10
**content props encounter meta provider name:** Dr. P. Stevens
**content props encounter meta provider specialty:** Unknown
**content props encounter meta ui risk color:** yellow
**content props encounter assessment impression:** Follow-up regarding normalization of liver function tests and initiation of Methotrexate for rheumatoid arthritis management. Normalization of LFTs with ALT at 35 U/L. Negative workup for chronic liver conditions. Likely transient elevation possibly related to MASLD. Cleared for Methotrexate initiation.
**content props encounter assessment differential 0:** Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
**content props encounter assessment differential 1:** Acute self-limiting liver episode
**content props encounter chief complaint:** Follow-up regarding normalization of liver function tests (LFTs) and potential initiation of Methotrexate for rheumatoid arthritis management.
**content props encounter hpi:** Since the previous review, Sarah reports increased adherence to dietary advice and gentle walking most days, noting a ~1.5 kg weight loss since March. Comprehensive hepatitis workup (viral, autoimmune, metabolic) returned negative. ALT has decreased to 35 U/L, suggesting transient elevation. Patient is considered low-risk for MTX initiation.
**content props encounter physical exam general:** Vital Signs: BP 140/88 mmHg (sitting), HR 78 bpm, RR 15/min, Temp 36.6°C, SpO₂ 99% on room air.
**content props encounter physical exam msk:** 
**content props encounter physical exam other systems:** Anthropometrics: Weight 84 kg (BMI 31.2 kg/m²).
**content props encounter plan investigations labs 0:** LFTs every 6 weeks
**content props encounter plan investigations labs 1:** FBC every 6 weeks
**content props encounter plan management follow up:** Follow-up appointment set for early August to review treatment response, adherence to monitoring, and adjust plan. Instructed to begin Methotrexate on 2024-06-03. Emphasized adherence to strict 6-weekly monitoring schedule.
**content props encounter plan management medications started 0 dose:** 7.5mg
**content props encounter plan management medications started 0 frequency:** weekly
**content props encounter plan management medications started 0 name:** Methotrexate
**content props encounter plan management medications started 0 route:** Unknown
**content props encounter plan management medications started 1 dose:** 5mg
**content props encounter plan management medications started 1 frequency:** weekly
**content props encounter plan management medications started 1 name:** Folic acid
**content props encounter plan management medications started 1 route:** Unknown
**content props encounter reason for visit:** Follow-up for liver function tests and rheumatoid arthritis management.
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 43
**content props encounterIndex:** 3
**content props dataSource:** Electronic Health Record
**createdAt:** 2025-10-15T08:00:00.000Z
**updatedAt:** 2025-10-15T08:00:00.000Z

# Object Record 14
**objectId:** raw-nervecentre-encounter-1
**type:** component
**componentType:** RawClinicalNote
**description:** Nervecentre Lab Alert with Highlighted Key Information
**content title:** Nervecentre - Encounter 1
**content component:** RawClinicalNote
**content props encounterNumber:** 1
**content props date:** 2024-03-05
**content props visitType:** Outpatient
**content props provider:** Dr. P. Stevens
**content props specialty:** MRCGP
**content props rawText:** ### Nervecentre

**Module:** Laboratory Alerting & Task Management
**Event Type:** Automated Laboratory Alert – LFT Derangement 

---

#### 1. Alert Event Summary

* **System Alert ID:** NC-LFT-20240305-001
* **Patient:** Sarah Miller (MRN: SM43850603, DOB: 1981-06-03, Age 43, F) 
* **Linked Encounter:**

  * Visit Type: Outpatient – General Practice
  * Date & Time: 2024-03-05 @ 10:15:22 (GMT+01:00)
  * Clinician: Dr. P. Stevens, MD, MRCGP 
* **Ordering Provider:** Dr. P. Stevens
* **Requesting Location:** GP Clinic – Room 3

---

#### 2. Trigger Details

* **Trigger Rule:** Rule ID 4.2 – *ALT ≥ 1.5 × ULN*
* **Analyte:** Alanine Aminotransferase (ALT)
* **Result:** 78 U/L (ULN: 40 U/L; 1.95 × ULN) 
* **Associated LFTs at Time of Alert:** 

  * AST: 55 U/L (H, <35)
  * ALP: 105 U/L (N, 30–130)
  * Bilirubin (Total): 12 μmol/L (N, <21)
  * INR: 1.0 (N, 0.8–1.2)
  * Platelets: 250 × 10⁹/L (N, 150–400)
* **Pattern of Injury:** Hepatocellular (AST/ALT ratio ≈ 0.7; no cholestasis)
* **Alert Level:** Level 2 – Non-Critical, Mandatory Acknowledgment within 72 hours
* **Severity Banding (System):**

  * ALT 1.5–3 × ULN → *Moderate Elevation*
  * Bilirubin normal, INR normal → *No acute liver failure criteria*

---

#### 3. Distribution & Delivery Log

* **Primary Recipient:**

  * Dr. P. Stevens (Responsible GP / LFT Ordering Clinician)
* **Secondary Visibility:**

  * GP Practice LFT Review Pool (Monitoring queue, “GP-LFT-MONITOR”)
* **Delivery Channels:**

  * Nervecentre mobile app push notification to Dr. Stevens
  * Medilogik Inbox message (flagged ‘LFT abnormal – review required’)
  * Alert icon added to Sarah Miller’s digital chart (LFT flag)

**Delivery Timeline:**

1. **2024-03-05 10:17:02** – LFT panel verified in LIS; HL7 message received by Nervecentre.
2. **2024-03-05 10:17:10** – Rule ID 4.2 fired (ALT 78 U/L ≥ 1.5 × ULN).
3. **2024-03-05 10:17:15** – Level 2 alert created and queued.
4. **2024-03-05 10:17:20** – Push notification sent to Dr. Stevens’ device and Medilogik Inbox.
5. **2024-03-05 10:17:25** – Chart flag updated (amber LFT icon).

---

#### 4. Acknowledgment & Escalation Logic

* **Acknowledgment Requirement:**

  * Alert must be electronically acknowledged by the responsible clinician **within 72 hours** of creation.

* **Current Status:**

  * Acknowledgement: **Pending**
  * Last System Check: 2024-03-05 18:00 – *No user interaction recorded.*

* **Scheduled Reminders:**

  * **+24 hours (2024-03-06 10:17)** – In-app reminder to Dr. Stevens (planned).
  * **+48 hours (2024-03-07 10:17)** – Second reminder and addition to GP practice “Unacknowledged LFT” dashboard (planned).
  * **+72 hours (2024-03-08 10:17)** – If still unacknowledged, auto-escalate to:

    * GP Duty Doctor / Clinical Lead inbox
    * Practice admin queue: “Follow-up abnormal results – contact clinician”.

* **Escalation Rule:**

  * Rule ID 7.1 – *Unacknowledged Level 2 lab alert >72 h → escalate to on-call / clinical lead.*

---

#### 5. Linked Tasks (Automatic)

1. **Task ID:** NC-TASK-20240305-ALT-REVIEW

   * **Title:** Review abnormal LFT (ALT 78 U/L) and document plan.
   * **Owner:** Dr. P. Stevens
   * **Priority:** Medium
   * **Due Date/Time:** 2024-03-08 10:15 (72h from encounter)
   * **Completion Status:** Open
   * **Task Notes (Pre-populated):**

     * “ALT 78 U/L (~1.95 × ULN), hepatocellular pattern, no bilirubin or INR derangement. Consider MASLD, NSAID use, and DMARD candidacy (planned MTX). Document clinical correlation, repeat LFT interval, and DMARD decision.”

2. **Task ID:** NC-TASK-20240305-MASLD-COUNSEL

   * **Title:** Confirm lifestyle counselling & weight-loss plan for suspected MASLD.
   * **Owner:** GP Practice Nurse / Health Coach (Pool: ‘MASLD-COACH’)
   * **Priority:** Low
   * **Due Date/Time:** 2024-03-19 09:00
   * **Status:** Open

---

#### 6. Safety & Governance Notes

* **Protocol Reference:**

  * Local GP LFT Policy v3.1 – “Any ALT ≥ 1.5 × ULN requires documented review and repeat LFT within 3–6 months, sooner if planning hepatotoxic medication (e.g., Methotrexate).”
* **Clinical Risk Comment (System):**

  * Flag added: “Planned DMARD (MTX) – ensure LFT trend and chronic liver disease screen BEFORE initiation.”
* **Audit Trail (Extract):**

  * 2024-03-05 10:17 – Alert generated automatically (System).
  * 2024-03-05 10:17 – Delivery confirmed to device ‘STEVENS_GP_IPHONE’.
  * 2024-03-05 10:18 – Chart flag updated (System).
  * *No user acknowledgment recorded yet.*


**content props dataSource:** Nervecentre
**content props highlights 0 text:** Rule ID 4.2 – *ALT ≥ 1.5 × ULN*
**content props highlights 0 color:** yellow
**content props highlights 1 text:** **Result:** 78 U/L (ULN: 40 U/L; 1.95 × ULN)
**content props highlights 1 color:** yellow
**content props highlights 2 text:** AST: 55 U/L (H, <35)
**content props highlights 2 color:** yellow
**content props highlights 3 text:** Severity Banding (System):
**content props highlights 3 color:** yellow
**content props highlights 4 text:** ALT 1.5–3 × ULN → *Moderate Elevation*
**content props highlights 4 color:** yellow
**content props highlights 5 text:** Local GP LFT Policy v3.1 – “Any ALT ≥ 1.5 × ULN requires documented review and repeat LFT within 3–6 months, sooner if planning hepatotoxic medication (e.g., Methotrexate).”
**content props highlights 5 color:** yellow
**content props highlights 6 text:** Planned DMARD (MTX) – ensure LFT trend and chronic liver disease screen BEFORE initiation.”
**content props highlights 6 color:** yellow
**createdAt:** 2025-11-17T12:00:00.000Z
**updatedAt:** 2025-11-17T12:00:00.000Z

# Object Record 7
**objectId:** raw-medilogik-ems-colonoscopy
**type:** component
**componentType:** RawClinicalNote
**description:** Medilogik DMARD Safety Monitoring with Highlights
**content title:** Medilogik - Outpatient
**content component:** RawClinicalNote
**content props encounterNumber:** 4
**content props date:** 2024-06-03
**content props visitType:** Outpatient
**content props provider:** Dr. P. Stevens
**content props specialty:** MRCGP
**content props rawText:** 
**Medilogik**
**Task Group:** DMARD Safety Monitoring & Patient Engagement Workflow
**Created By:** Dr. P. Stevens, MD, MRCGP
**Date Created:** 2024-06-03
**Priority:** **High**
**Status:** Active
**Task ID:** **MTX_MONITOR_SM_01_RECUR**
**Associated Encounter:** Outpatient – Methotrexate Initiation Consultation

---

## **1. Task Description (Expanded)**

“Establish a comprehensive Methotrexate (MTX) monitoring workflow for Sarah Miller following initiation of 7.5 mg weekly MTX therapy for Rheumatoid Arthritis.
The objective is to ensure safe continuation of MTX, early detection of hepatotoxicity, cytopenias, or intolerance, and reinforcement of adherence to patient education and safety-netting protocols.”

---

# **2. Monitoring Schedule (Detailed)**

### **Initial Post-Initiation Assessment**

* **Due Date:** **2024-07-15**
* **Tests Required:**

  * Full Liver Function Panel (ALT, AST, ALP, GGT, Bilirubin, INR)
  * Full Blood Count (FBC)
* **Purpose:**

  * Assess early hepatic response to MTX
  * Detect early cytopenias
  * Evaluate need for dose adjustment or pause

---

### **Ongoing Routine Monitoring**

* **Frequency:** Every **6 weeks**
* **Duration:** First 6 months (June–December 2024)
* **Tests at each interval:**

  * **LFT**
  * **FBC**
  * **Renal Profile (U+E)**
  * **CRP (optional, if RA control uncertain)**

### **Post-6-Month Monitoring**

* If stable → move to **every 8–12 weeks** per DMARD safety protocol.

---

# **3. Medilogik Auto-Alert Configuration**

### **High-Priority Auto-Alerts (Immediate clinician notification)**

* **ALT > 2× ULN (>80 U/L)**
* **AST > 2× ULN**
* **Platelets < 150 ×10⁹/L**
* **Neutrophils <1.5 ×10⁹/L**
* **WBC <3.0 ×10⁹/L**
* **Bilirubin rising trend across two tests**

**Action Trigger:**
→ Display interruptive alert in Medilogik clinician inbox
→ Flag patient chart with **“DMARD Safety Alert – Review Required”**

---

### **Moderate-Priority Auto-Alerts**

* **Gradual ALT rise but < 2× ULN**
* **New macrocytosis**
* **eGFR decline**
  → Routed to GP monitoring pool for review within 72 hours.

---

# **4. Associated Patient Education Tasks**

### **Patient Education Pack Delivery**

* Includes:

  * MTX Information Leaflet (British Society for Rheumatology standard)
  * Liver toxicity symptoms sheet
  * Medication schedule card (MTX + folic acid)
* Marked as **Completed – Provided in clinic, 2024-06-03**

---

### **Compliance Check Call**

* **Scheduled:** 7 days post initiation (2024-06-10)
* **Purpose:**

  * Confirm correct dosing (once weekly only)
  * Verify folic acid timing
  * Screen for early side effects
* Responsible Team: GP Support / Clinical Pharmacist

---

### **Alcohol Intake Advisory**

* Task to review patient’s alcohol intake at each monitoring appointment
* Documented baseline: “Patient consumes 12 units/week”
* Goal: Reduce to < 6 units/week for MTX safety

---

# **5. Clinical Safety & Governance Notes**

* MTX initiation authorized based on:

  * ALT normalization (ALT 35)
  * Negative viral hepatitis screen
  * Negative autoimmune hepatitis screen
  * Normal synthetic liver profile
  * Low Fib-4 (0.9)

* MASLD acknowledged as background risk; enhanced vigilance maintained.

* MTX classified as a **high-risk drug**, requiring strict adherence to monitoring timeline.

* Medilogik will:

  * Log missed tests
  * Auto-generate overdue notices after 48 hours
  * Escalate persistent failures to GP clinical lead

---

# **6. Follow-Up & Tracking**

### **Next Steps**

* **Next scheduled test:** 2024-07-15
* **Next clinician review:** Early August appointment already booked
* **Rheumatology liaison:** If RA control insufficient at 12 weeks, Medilogik flags GP to consider rheumatology review

### **Dashboard Integration**

Medilogik integrates with the practice DMARD dashboard:

* Displays latest LFT/FBC trends
* Risk colour-coding (Green → Amber → Red)
* Task completion metrics

Sarah is currently classified as:
**Amber – New MTX Start (requires intensified monitoring)**

---

**content props dataSource:** Medilogik
**content props highlights 0 text:** ALT > 2× ULN (>80 U/L)
**content props highlights 0 color:** red
**content props highlights 1 text:** AST > 2× ULN
**content props highlights 1 color:** red
**content props highlights 2 text:** Bilirubin rising trend across two tests
**content props highlights 2 color:** red
**content props highlights 3 text:** Gradual ALT rise but < 2× ULN
**content props highlights 3 color:** yellow
**content props highlights 4 text:** Patient consumes 12 units/week
**content props highlights 4 color:** yellow
**content props highlights 5 text:** * MTX initiation authorized based on:

  * ALT normalization (ALT 35)
**content props highlights 5 color:** green
**content props highlights 6 text:** Negative viral hepatitis screen
**content props highlights 6 color:** green
**content props highlights 7 text:** Negative autoimmune hepatitis screen
**content props highlights 7 color:** green
**content props highlights 8 text:** Normal synthetic liver profile
**content props highlights 8 color:** green
**content props highlights 9 text:** Low Fib-4 (0.9)
**content props highlights 9 color:** green
**content props highlights 10 text:** MASLD acknowledged as background risk; enhanced vigilance maintained.
**content props highlights 10 color:** yellow
**content props highlights 11 text:** * MTX classified as a **high-risk drug**, requiring strict adherence to monitoring timeline.
**content props highlights 11 color:** yellow
**createdAt:** 2025-11-17T15:00:00.000Z
**updatedAt:** 2025-11-17T15:00:00.000Z